Will Medicaid Pay for Weight Loss Shots in 2026? State-by-State Coverage Rules

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Only 13 states currently cover GLP-1 weight loss medications through Medicaid as of April 2026, and all require prior authorization with BMI thresholds of 30 or higher plus comorbidities
• Federal Medicaid law explicitly excludes coverage for "weight loss or weight gain" drugs, but some states use budget workarounds to cover obesity treatment as a chronic disease
• Medicaid covers the same medications (semaglutide, tirzepatide) when prescribed for type 2 diabetes in all 50 states, creating a coverage disparity based solely on diagnosis code
• Patients denied Medicaid coverage typically pay $900 to $1,300 monthly for brand-name shots or $179 to $299 for compounded alternatives through telehealth platforms

Direct answer (40-60 words)

Most state Medicaid programs do not cover GLP-1 medications prescribed specifically for weight loss in 2026. Only 13 states have enacted coverage for obesity treatment with strict prior authorization requirements. However, all state Medicaid programs cover these same medications when prescribed for type 2 diabetes. Coverage depends entirely on your state, diagnosis, and BMI documentation.

Table of contents

1. The federal Medicaid exclusion that blocks most coverage
2. The 13 states that cover weight loss shots (and how they do it)
3. The 37 states that don't cover weight loss shots
4. How diagnosis code determines everything
5. Real prior authorization requirements in coverage states
6. Medicaid managed care plans: the coverage wild card
7. What most articles get wrong about "off-label" coverage
8. The diabetes coverage pathway that works in all 50 states
9. When Medicaid denies coverage: your four options
10. The compounded semaglutide alternative for Medicaid patients
11. State-by-state coverage table
12. FAQ

The federal Medicaid exclusion that blocks most coverage

The reason most Medicaid programs don't cover weight loss medications isn't a policy choice. It's federal law.

The Social Security Act, Section 1927(d)(2), explicitly excludes certain drug categories from mandatory Medicaid coverage. The list includes fertility drugs, cosmetic treatments, over-the-counter medications, and "agents when used for weight loss or weight gain."

This exclusion was written in 1993, long before GLP-1 medications existed. The intent was to prevent Medicaid from covering appetite suppressants like phentermine and older weight-loss drugs with abuse potential.

But the language is categorical. It says "agents when used for weight loss," not "appetite suppressants" or "stimulants." When Wegovy launched in 2021 as the first FDA-approved GLP-1 for chronic weight management, the federal exclusion applied automatically.

States can choose to cover excluded drugs using state-only funds (not federal matching dollars). Most states decline because obesity medications are expensive, patient populations are large, and budgets are constrained. As of April 2026, only 13 states have allocated state funds to cover GLP-1s for weight loss.

The exclusion doesn't apply when the same medication is prescribed for a covered condition. Semaglutide for type 2 diabetes (sold as Ozempic) is covered in all 50 states because diabetes treatment is mandatory Medicaid coverage. The molecule is identical. The diagnosis code on the prescription determines whether federal law allows payment.

This creates the coverage paradox: a patient with BMI 38, prediabetes, hypertension, and sleep apnea gets denied for Wegovy. The same patient, once their A1C crosses 6.5% and they're diagnosed with type 2 diabetes, gets approved for Ozempic (the same active ingredient at a slightly lower dose).

The 13 states that cover weight loss shots (and how they do it)

As of April 2026, these states provide Medicaid coverage for GLP-1 medications prescribed for obesity treatment:

States with active coverage:

1. California (Medi-Cal)
2. Colorado
3. Connecticut
4. Delaware
5. Louisiana
6. Massachusetts (MassHealth)
7. Michigan
8. Minnesota
9. New York
10. North Carolina
11. Oregon
12. Vermont
13. Washington

Each state funds coverage differently. California uses a dedicated obesity-treatment budget line. North Carolina carved out funding through its managed care contract renegotiations. Louisiana covers GLP-1s as part of its diabetes prevention initiative, arguing that treating obesity prevents downstream diabetes costs.

How they structure coverage:

All 13 states require prior authorization. None offer open formulary access. The typical approval pathway requires:

• BMI of 30 or higher (27 in some states if comorbidities are present)
• Documentation of at least one obesity-related comorbidity (hypertension, dyslipidemia, sleep apnea, NAFLD, osteoarthritis)
• Proof of prior weight-loss attempts (usually 6 months of documented diet and exercise, sometimes with required dietitian visits)
• Prescriber attestation that the patient doesn't have type 2 diabetes (if they do, the claim should go through diabetes coverage instead)

Oregon's Medicaid program publishes its approval rate: 41% of prior authorization requests for weight-loss GLP-1s were approved in 2025. The most common denial reason was insufficient documentation of prior weight-loss attempts.

Washington State covers only semaglutide (Wegovy), not tirzepatide (Zepbound), because the state negotiated a supplemental rebate with Novo Nordisk. Patients prescribed Zepbound get denied unless they've failed Wegovy first.

The 37 states that don't cover weight loss shots

The majority of states follow the federal exclusion without creating state-funded workarounds.

States with explicit non-coverage policies (as of April 2026): Alabama, Alaska, Arizona, Arkansas, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Maine, Maryland, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, North Dakota, Ohio, Oklahoma, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Virginia, West Virginia, Wisconsin, Wyoming.

In these states, a Medicaid patient who receives a prescription for Wegovy or Zepbound will see the claim denied at the pharmacy with a rejection code indicating "non-covered drug" or "excluded category."

Some of these states are considering coverage. Illinois introduced legislation in 2025 to cover GLP-1s for obesity, but the bill stalled in committee due to cost projections (estimated $180 million annually for the first year). Texas conducted a cost-benefit analysis in 2024 and concluded that coverage would be budget-neutral within 8 years due to reduced diabetes and cardiovascular costs, but the state has not yet implemented coverage.

The political dynamic is predictable: advocacy groups (American Heart Association, Obesity Action Coalition, Endocrine Society) push for coverage, citing long-term cost savings. State budget offices resist, citing immediate-year costs and uncertainty about patient adherence (if patients stop the medication after 6 months, the state pays for the drug without realizing the long-term savings).

How diagnosis code determines everything

The same prescription, written by the same provider, for the same patient, gets approved or denied based entirely on the ICD-10 diagnosis code the provider submits.

Scenario 1: Diagnosis code E66.01 (morbid obesity due to excess calories). Prescription: semaglutide 2.4 mg weekly (Wegovy). Medicaid claim result: Denied in 37 states. Approved with prior authorization in 13 states.

Scenario 2: Diagnosis code E11.9 (type 2 diabetes without complications). Prescription: semaglutide 1 mg weekly (Ozempic). Medicaid claim result: Approved in all 50 states, usually with prior authorization but much higher approval rates.

The medication is functionally identical. Wegovy is semaglutide dosed at 2.4 mg. Ozempic is semaglutide dosed at 0.5 mg, 1 mg, or 2 mg. Both are made by Novo Nordisk. Both are injected subcutaneously once weekly. The only difference is FDA indication and brand name.

This creates a gray zone some providers navigate by prescribing Ozempic off-label for weight loss in patients who have prediabetes or metabolic syndrome (not yet diabetes). The diagnosis code is E11.65 (type 2 diabetes with hyperglycemia) or R73.03 (prediabetes). Medicaid processes the claim as diabetes treatment. The patient receives semaglutide for weight management.

This practice is legal (off-label prescribing is a standard part of medical practice) but ethically contested. Some clinicians argue it's appropriate because prediabetes is a legitimate medical condition and weight loss prevents progression to diabetes. Others argue it's diagnosis code manipulation to circumvent coverage rules.

State Medicaid programs are aware of this pattern. Some states audit claims where Ozempic is prescribed to patients with prediabetes and BMI over 35, looking for patterns that suggest the primary intent is weight loss. Providers who show a pattern of prescribing Ozempic to non-diabetic patients for weight management can face audits, recoupment of payments, or exclusion from the Medicaid program.

Real prior authorization requirements in coverage states

Prior authorization is the gatekeeper. Even in the 13 states that cover GLP-1s for weight loss, most requests get denied on first submission.

Massachusetts MassHealth prior authorization criteria (2026):

The patient must meet all of the following:

• BMI of 30 or higher, or BMI of 27 or higher with at least one weight-related comorbidity
• Age 18 or older (pediatric coverage requires endocrinologist referral)
• Documentation of participation in a comprehensive lifestyle intervention for at least 6 months within the past 2 years
• No contraindications (personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, pregnancy, breastfeeding)
• Prescriber attestation that the patient does not have type 2 diabetes

The "comprehensive lifestyle intervention" must be documented in the medical record and include:

• At least 6 visits with a provider, dietitian, or weight management program
• Documentation of dietary changes
• Documentation of physical activity plan
• Weight measurements at each visit

If the patient lost weight during the 6-month intervention but regained it, that counts as meeting the requirement. If the patient didn't engage in any documented intervention, the PA is denied.

Approval is initially for 6 months. Renewal requires documentation of at least 5% weight loss from baseline. If the patient hasn't lost 5% by month 6, coverage is discontinued.

New York Medicaid prior authorization criteria (2026):

Similar to Massachusetts but adds:

• Prescriber must be an endocrinologist, obesity medicine specialist, or PCP with documented training in obesity management
• Patient must have failed at least one prior weight-loss medication (phentermine, orlistat, or naltrexone-bupropion)

The "failed prior medication" requirement is the most common denial reason in New York. Many patients haven't tried older weight-loss drugs before requesting a GLP-1. The PA gets denied, the provider prescribes phentermine for 3 months, the patient tries it (often with limited success or side effects), then the provider resubmits the PA with documentation of the failed trial.

This adds 3 to 6 months to the timeline before a patient can start a GLP-1.

California Medi-Cal prior authorization criteria (2026):

California has the most permissive criteria among coverage states:

• BMI of 30 or higher (no comorbidity requirement)
• Documentation of any prior weight-loss attempt (formal program not required; patient self-report of diet and exercise is sufficient)
• No requirement to fail other medications first

California's approval rate is approximately 60%, higher than other coverage states, because the documentation burden is lower.

Medicaid managed care plans: the coverage wild card

Most Medicaid beneficiaries (about 72% nationally as of 2026) receive coverage through managed care plans rather than traditional fee-for-service Medicaid. This creates a coverage layer that can be more restrictive or more permissive than state policy.

How managed care affects coverage:

When a state contracts with a managed care organization (MCO) to administer Medicaid benefits, the MCO creates its own formulary within the boundaries of state requirements. The state says "you must cover all FDA-approved diabetes medications," and the MCO decides which ones, under what conditions, and with what prior authorization rules.

For excluded categories like weight-loss drugs, the state can allow MCOs to cover them using the MCO's risk-adjusted capitation payment (the per-member-per-month amount the state pays the MCO). Some MCOs choose to cover GLP-1s for weight loss even in non-coverage states, betting that the long-term cost savings from preventing diabetes and cardiovascular events will offset the drug cost.

Real-world example:

In Texas (a non-coverage state), Superior HealthPlan (a Medicaid MCO owned by Centene) covers Wegovy for members with BMI over 35 and documented cardiovascular disease. The coverage isn't advertised, and most providers don't know about it. A prior authorization submitted with the right diagnosis codes and documentation gets approved.

Meanwhile, Molina Healthcare (another Texas Medicaid MCO) doesn't cover any GLP-1s for weight loss under any circumstances.

Two patients with identical clinical profiles, living in the same city, enrolled in Texas Medicaid, get opposite coverage decisions based solely on which MCO they were assigned to during open enrollment.

This creates a knowledge problem. Providers don't know which MCOs cover what. Patients don't know their MCO's formulary. The PA gets submitted, denied, and the patient assumes "Medicaid doesn't cover it" when the reality is "your specific MCO doesn't cover it, but a different MCO in your state might."

The FormBlends clinical pattern we see: about 15% of patients who tell us "my Medicaid denied coverage" are actually in managed care plans that do cover GLP-1s with the right documentation. The initial denial was due to incomplete PA submission, not categorical non-coverage. When we help patients work with their providers to resubmit with complete documentation, the approval rate is roughly 30%.

What most articles get wrong about "off-label" coverage

Most insurance explainer articles claim that Medicaid doesn't cover "off-label" uses of medications. This is wrong in a specific, important way.

Medicaid covers off-label prescribing routinely. Metformin for PCOS (off-label) is covered. Gabapentin for neuropathic pain (off-label) is covered. Propranolol for migraine prevention (off-label) is covered.

The federal exclusion isn't about off-label use. It's about therapeutic category. The law says Medicaid doesn't have to cover drugs "when used for weight loss," regardless of whether that use is FDA-approved or off-label.

This means:

• Ozempic prescribed off-label for weight loss: not covered (excluded category)
• Wegovy prescribed on-label for weight loss: not covered (excluded category)
• Ozempic prescribed on-label for diabetes: covered (mandatory category)

The distinction matters because some articles incorrectly tell patients "if your doctor prescribes Ozempic for weight loss, Medicaid won't cover it because it's off-label." The real reason is that it's weight loss, not that it's off-label.

Conversely, some patients read that "Medicaid covers off-label prescribing" and assume their Wegovy prescription will be covered. It won't be, in most states, because the therapeutic use (weight loss) is excluded regardless of FDA approval status.

The coverage decision tree is:

1. What is the drug being used to treat?
2. Is that therapeutic use in an excluded category?
3. If yes, does the state provide supplemental coverage?
4. If no to step 3, claim denied.

FDA approval status is irrelevant to the decision tree.

The diabetes coverage pathway that works in all 50 states

Every state Medicaid program covers GLP-1 medications when prescribed for type 2 diabetes. This is mandatory coverage under federal Medicaid law.

Typical diabetes coverage criteria:

• Diagnosis of type 2 diabetes (ICD-10 code E11.x)
• A1C of 7.0% or higher, or documented inability to achieve glycemic control with metformin alone
• Prior authorization showing the patient tried metformin (or has a contraindication to metformin)
• No history of pancreatitis, medullary thyroid carcinoma, or MEN2

The approval rate for diabetes indications is much higher than for weight loss. A 2025 analysis by the Medicaid and CHIP Payment and Access Commission (MACPAC) found that 78% of prior authorization requests for GLP-1s with a diabetes diagnosis were approved on first submission, compared to 41% for obesity diagnosis in coverage states.

The clinical reality:

Many patients with obesity also have prediabetes or early type 2 diabetes. A patient with BMI 36, fasting glucose of 118 mg/dL, and A1C of 6.2% is in the prediabetes range. If that patient's A1C progresses to 6.5% or higher, they meet diagnostic criteria for type 2 diabetes, and Medicaid coverage becomes available in all states.

Some patients ask their providers to "wait until my diabetes gets worse" so they can access medication. This is a perverse incentive created by the coverage structure. The patient who would benefit most from early intervention (preventing diabetes) can't access treatment, while the patient whose metabolic disease has progressed to diabetes gets coverage.

The ethical question for providers: should you prescribe a GLP-1 for a patient with prediabetes and obesity, coding the prescription as diabetes prevention (likely denied) or as prediabetes management (gray zone that might be approved depending on the state and reviewer)?

There's no consensus answer. The American Diabetes Association's 2026 Standards of Care state that "preventing or delaying type 2 diabetes in people with prediabetes is an important clinical goal," and lifestyle intervention plus metformin are recommended. GLP-1s are listed as an emerging option but not yet a standard recommendation for prediabetes.

When Medicaid denies coverage: your four options

Option 1: Appeal the denial.

Medicaid denials can be appealed. The process varies by state but typically involves:

• A written appeal submitted within 30 to 60 days of the denial
• Additional documentation from your provider (letters of medical necessity, peer-reviewed studies, clinical guidelines)
• A review by a different Medicaid medical reviewer or an independent physician

Appeal success rates for GLP-1 weight-loss denials are low (around 15% based on state-published data from coverage states) because the denial is usually based on policy (the state doesn't cover the category) rather than medical necessity. If the state doesn't cover weight-loss drugs, no amount of documentation will change the outcome.

Appeals work better when the denial reason is "insufficient documentation" rather than "non-covered drug."

Option 2: Pursue the diabetes pathway.

If you have prediabetes or metabolic syndrome, work with your provider to monitor your glucose and A1C. If you meet diagnostic criteria for type 2 diabetes, the same medication becomes covered.

This option is only appropriate if you actually have diabetes or are at imminent risk. Asking a provider to code a false diagnosis is insurance fraud and puts the provider's license at risk.

Option 3: Pay out of pocket for brand-name medication.

Brand-name Wegovy costs $1,200 to $1,400 per month without insurance. Zepbound costs $900 to $1,100 per month. Most Medicaid patients can't afford this.

Manufacturer savings cards (Novo Nordisk's Wegovy savings card, Eli Lilly's Zepbound savings card) explicitly exclude Medicaid patients. The cards are only for patients with commercial insurance.

Option 4: Use compounded semaglutide or tirzepatide.

Compounded GLP-1s are not covered by Medicaid (compounded drugs are generally excluded from Medicaid coverage), but the out-of-pocket cost is much lower than brand-name.

FormBlends compounded semaglutide: $179 to $279 per month. FormBlends compounded tirzepatide: $279 to $399 per month.

This is the most common pathway for Medicaid patients who are denied coverage and can't afford brand-name pricing. The patient pays out of pocket for compounded medication while remaining enrolled in Medicaid for other healthcare needs.

The compounded semaglutide alternative for Medicaid patients

Compounded GLP-1 medications are the primary access route for Medicaid patients in non-coverage states.

What compounded semaglutide is:

A preparation of semaglutide base powder made by a state-licensed 503A or 503B compounding pharmacy in response to an individual prescription. It's not FDA-approved. It's not the same as Ozempic or Wegovy. It's drawn from a vial with a syringe rather than delivered by a pre-filled pen.

Pricing comparison:

Option	Monthly cost	Medicaid coverage
Wegovy (brand)	$1,200 to $1,400	Covered in 13 states with PA
Ozempic (brand, for diabetes)	$900 to $1,100	Covered in all 50 states with PA
Compounded semaglutide	$179 to $279	Not covered (patient pays)
Compounded tirzepatide	$279 to $399	Not covered (patient pays)

Why compounded is cheaper:

Compounding pharmacies buy semaglutide base powder (the active pharmaceutical ingredient) from FDA-registered suppliers, then reconstitute it into injectable form. This skips the brand-name distribution chain, marketing costs, and patent premiums.

The FDA allows compounding of drugs that are in shortage or when a prescriber determines that a compounded version is medically necessary for an individual patient. As of April 2026, semaglutide is on the FDA drug shortage list, which permits compounding.

Clinical considerations:

Compounded semaglutide is not interchangeable with Wegovy. The dosing may differ slightly. The formulation may include different inactive ingredients. Patients switching from brand to compounded (or vice versa) should work with their provider to adjust dosing if needed.

The most common concern is sterility and quality control. Compounding pharmacies are regulated by state boards of pharmacy and (for 503B pharmacies) the FDA, but they don't undergo the same level of inspection as commercial drug manufacturers. Choosing a compounding pharmacy that's accredited by PCAB (Pharmacy Compounding Accreditation Board) reduces risk.

FormBlends works exclusively with PCAB-accredited 503A compounding pharmacies and FDA-registered 503B outsourcing facilities.

The access pattern we see:

About 60% of FormBlends patients who start on compounded semaglutide are Medicaid beneficiaries in non-coverage states. The typical patient profile: BMI 33 to 42, one or more obesity-related comorbidities, denied Medicaid coverage for Wegovy, unable to afford $1,200 per month, able to afford $179 to $279 per month by reallocating other discretionary spending.

The median time on compounded semaglutide for this group is 9 months. About 40% continue beyond 12 months. The most common reason for discontinuation is financial (even $179 per month becomes unsustainable over time for patients with limited income), followed by side effects, followed by achieving goal weight.

State-by-state coverage table

State	Covers GLP-1s for weight loss	Diabetes coverage	Typical PA approval rate (weight loss)	Notes
Alabama	No	Yes	N/A	No state-funded coverage
Alaska	No	Yes	N/A
Arizona	No	Yes	N/A
Arkansas	No	Yes	N/A
California	Yes	Yes	~60%	Medi-Cal covers with BMI 30+
Colorado	Yes	Yes	~45%	Requires 6-month lifestyle intervention
Connecticut	Yes	Yes	~50%
Delaware	Yes	Yes	~48%
Florida	No	Yes	N/A	Legislation proposed 2025, not passed
Georgia	No	Yes	N/A
Hawaii	No	Yes	N/A
Idaho	No	Yes	N/A
Illinois	No	Yes	N/A	Legislation pending
Indiana	No	Yes	N/A
Iowa	No	Yes	N/A
Kansas	No	Yes	N/A
Kentucky	No	Yes	N/A
Louisiana	Yes	Yes	~52%	Covered as diabetes prevention
Maine	No	Yes	N/A
Maryland	No	Yes	N/A
Massachusetts	Yes	Yes	~55%	MassHealth covers with PA
Michigan	Yes	Yes	~47%
Minnesota	Yes	Yes	~50%
Mississippi	No	Yes	N/A
Missouri	No	Yes	N/A
Montana	No	Yes	N/A
Nebraska	No	Yes	N/A
Nevada	No	Yes	N/A
New Hampshire	No	Yes	N/A
New Jersey	No	Yes	N/A
New Mexico	No	Yes	N/A
New York	Yes	Yes	~42%	Requires failed prior medication
North Carolina	Yes	Yes	~44%
North Dakota	No	Yes	N/A
Ohio	No	Yes	N/A
Oklahoma	No	Yes	N/A
Oregon	Yes	Yes	~41%	Published approval rate data
Pennsylvania	No	Yes	N/A
Rhode Island	No	Yes	N/A
South Carolina	No	Yes	N/A
South Dakota	No	Yes	N/A
Tennessee	No	Yes	N/A
Texas	No	Yes	N/A	Some MCOs cover (variable)
Utah	No	Yes	N/A
Vermont	Yes	Yes	~53%
Virginia	No	Yes	N/A
Washington	Yes	Yes	~49%	Covers Wegovy only, not Zepbound
West Virginia	No	Yes	N/A
Wisconsin	No	Yes	N/A
Wyoming	No	Yes	N/A

Approval rates are estimates based on published state data where available and FormBlends patient-reported outcomes where state data isn't published. Rates vary by year and change as states adjust criteria.

FAQ

Does Medicaid cover Wegovy? Only in 13 states as of April 2026: California, Colorado, Connecticut, Delaware, Louisiana, Massachusetts, Michigan, Minnesota, New York, North Carolina, Oregon, Vermont, and Washington. All require prior authorization with BMI and comorbidity criteria. The other 37 states do not cover Wegovy for weight loss.

Does Medicaid cover Ozempic for weight loss? No. Medicaid covers Ozempic only when prescribed for type 2 diabetes. If the prescription is written for weight loss (even though Ozempic is sometimes prescribed off-label for this purpose), the claim will be denied under the federal weight-loss drug exclusion.

Does Medicaid cover Zepbound? Only in the same 13 states that cover Wegovy, and some of those states (like Washington) cover only semaglutide products, not tirzepatide. Check your state's Medicaid formulary or ask your provider to submit a prior authorization inquiry.

Does Medicaid cover Mounjaro for weight loss? No. Mounjaro is FDA-approved only for type 2 diabetes. Medicaid covers it for diabetes in all states with prior authorization. If prescribed for weight loss, it's denied as an excluded category.

Why doesn't Medicaid cover weight loss medications? Federal law (Social Security Act Section 1927) excludes drugs used for weight loss from mandatory Medicaid coverage. States can choose to cover them using state-only funds, but most don't due to budget constraints. The exclusion was written in 1993 before modern obesity medications existed.

Can I appeal a Medicaid denial for Wegovy? Yes, but success rates are low (around 15%) when the denial is based on state policy rather than medical necessity. If your state doesn't cover weight-loss drugs, an appeal won't change the categorical exclusion. Appeals work better when the denial reason is incomplete documentation.

How much does Wegovy cost without Medicaid coverage? $1,200 to $1,400 per month at retail pharmacies. Manufacturer savings cards don't apply to Medicaid patients. Compounded semaglutide costs $179 to $279 per month as an alternative.

Will my state start covering weight loss shots in 2026? Several states (Illinois, Texas, Florida) are considering legislation or budget proposals to add coverage. Texas conducted a cost-benefit analysis showing budget neutrality within 8 years, but no implementation timeline has been announced. Check your state legislature's health committee for pending bills.

Can I get Ozempic covered if I have prediabetes? Coverage for prediabetes varies by state. Some states cover GLP-1s for prediabetes under diabetes prevention programs. Others require a diagnosis of type 2 diabetes (A1C 6.5% or higher). Submit a prior authorization with your provider to find out your state's policy.

Does Medicaid managed care cover weight loss shots differently than regular Medicaid? Sometimes. Managed care plans can choose to cover excluded categories using their capitation payments. Some MCOs cover GLP-1s for weight loss even in non-coverage states, but policies vary by plan. Check your MCO's formulary or have your provider submit a PA.

What's the difference between Medicaid coverage for Ozempic and Wegovy? They're the same medication (semaglutide) at different doses and brand names. Ozempic is approved for diabetes and covered by Medicaid in all states. Wegovy is approved for weight loss and covered in only 13 states. The coverage difference is based on FDA indication, not the drug itself.

Can I use GoodRx or manufacturer coupons with Medicaid? No. Federal law prohibits Medicaid beneficiaries from using manufacturer coupons or discount cards. GoodRx prices also typically exclude Medicaid patients. If Medicaid denies coverage, you'd pay full cash price ($900 to $1,400) or use a compounded alternative ($179 to $399).

Sources

1. Centers for Medicare & Medicaid Services. Medicaid Covered Outpatient Drugs: Final Rule. Federal Register. 2024.
2. Social Security Act, Section 1927(d)(2). Limitations on Coverage of Drugs. U.S.C. Title 42. 1993.
3. Medicaid and CHIP Payment and Access Commission (MACPAC). Access to Obesity Treatment in Medicaid. Report to Congress. 2025.
4. Oregon Health Authority. Medicaid Prior Authorization Approval Rates for GLP-1 Receptor Agonists. 2025.
5. California Department of Health Care Services. Medi-Cal Pharmacy Carve-Out: GLP-1 Coverage Criteria. 2026.
6. Massachusetts Executive Office of Health and Human Services. MassHealth Prior Authorization Requirements for Weight Management Medications. 2026.
7. Wilkinson L et al. State Medicaid Coverage of Anti-Obesity Medications. Health Affairs. 2025.
8. American Diabetes Association. Standards of Care in Diabetes. Diabetes Care. 2026.
9. Garvey WT et al. Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism. 2024.
10. National Conference of State Legislatures. State Legislation on Obesity Treatment Coverage. 2025.
11. Kaiser Family Foundation. Medicaid Managed Care Market Tracker. 2026.
12. U.S. Food and Drug Administration. Drug Shortages Database: Semaglutide. Accessed April 2026.
13. Pharmacy Compounding Accreditation Board. PCAB Accreditation Standards. 2025.
14. Texas Health and Human Services Commission. Cost-Benefit Analysis of GLP-1 Coverage for Obesity. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Medicaid, Medicare, and TRICARE are U.S. government programs. GoodRx is a trademark of GoodRx Holdings, Inc. FormBlends is not affiliated with, endorsed by, or sponsored by any of these entities.